Lantern Pharma Inc.
LTRNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Lantern Pharma Inc. (LTRN) is listed under Biotechnology. The company carries a $9.5M market cap, placing it firmly in the micro-cap category. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
Market Cap
$9.5M
Beta
2.32
P/E (TTM)
—
P/E (Fwd)
-0.31
EPS (TTM)
$-1.57
EPS (Fwd)
$-2.02
ROE
-400.9%
ROA
-74.3%
Cash
$7.4M
Total Debt
$39,715
Free CF
-$8.2M
52W Change
-84.4%
Annual Financials
Cash vs Debt
Where LTRN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LTRN finished 73.88% below its 150-day moving average ($2.45) and 75.19% below its 200-day moving average ($2.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LTRN overbought or oversold?
At the October 20, 2026 close, LTRN's RSI(14) was 15.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $7.4M in cash and $40K in debt, LTRN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$8.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -400.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Lantern Pharma Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Lantern Pharma Inc. and its sector.